Related Experiment Video

Updated: Aug 21, 2026

Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

Muscarinic antagonist control of myopia: a molecular search for the M1 receptor in chick

George C Yin1, Alex Gentle, Neville A McBrien

  • 1Department of Optometry and Vision Sciences, The University of Melbourne, Victoria, Australia.

Molecular Vision
|November 5, 2004
PubMed
Abstract

Insights

Researchers investigated the M1 receptor in chicks to understand how pirenzepine slows myopia. The study found no evidence of the M1 receptor in chick tissues, suggesting pirenzepine may work through other mechanisms to inhibit myopia progression.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Molecular Biology

Background:

  • Pirenzepine, an M1 selective muscarinic antagonist, is known to slow myopia progression in humans and animals.
  • The mechanism of pirenzepine's action is presumed to involve M1 receptors, but M1 receptors have not been identified in chickens.

Purpose of the Study:

  • To determine if a genetic template for the M1 receptor is expressed or present in chick ocular and brain tissues.
  • To investigate the potential mechanism of pirenzepine's anti-myopia effect in chicks.

Main Methods:

  • Polymerase Chain Reaction (PCR) was used to detect M1 mRNA, gene, and promoter sequences.
  • Northern and Southern blotting analyses were employed for mRNA and gene detection.
  • Rat tissues served as positive controls, and M2 and M4 mRNA expression in chick retina was confirmed.

Main Results:

  • No M1 mRNA expression was detected in chick ocular and brain tissues via northern analysis.
  • PCR and Southern analyses confirmed the absence of M1 gene and promoter sequences in chicks.
  • Methodological validation was achieved through positive findings in rat tissues and detection of other muscarinic receptor subtypes in chick retina.

Conclusions:

  • The chick appears to lack an M1 receptor.
  • This suggests pirenzepine's inhibitory effect on myopia progression in chicks is unlikely to be mediated via M1 receptors.
  • Alternative mechanisms of action for pirenzepine in myopia control warrant further investigation.

More Related Videos

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.